Novel H-2D<sup>b</sup>-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice.
McAuliffe J. et al, (2024), Journal for immunotherapy of cancer, 12
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM. et al, (2023), Cancer cell, 41, 1222 - 1241.e7
Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression.
Ramirez-Valdez RA. et al, (2023), Cell reports, 42
Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes.
Solvay M. et al, (2023), Journal for immunotherapy of cancer, 11
Tumour immune rejection triggered by activation of α2-adrenergic receptors.
Zhu J. et al, (2023), Nature
Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression.
Finisguerra V. et al, (2023), Journal for immunotherapy of cancer, 11
Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer.
Naulaerts S. et al, (2023), Sci Transl Med, 15
Editorial: Heme proteins: key players in the regulation of immune responses.
Volpi C. et al, (2023), Front Immunol, 14
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC.
Leung CSK. and Van den Eynde BJ., (2022), Cancer Cell
New Insights into the Mechanisms of Proteasome-Mediated Peptide Splicing Learned from Comparing Splicing Efficiency by Different Proteasome Subtypes.
Ferrari V. et al, (2022), Journal of immunology (Baltimore, Md. : 1950)
T-cell mediated targeted delivery of anti-PD-L1 nanobody overcomes poor antibody penetration and improves PD-L1 blocking at the tumor site
Petit P-F. et al, (2022), Cancer Immunology Research
Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Lahman MC. et al, (2022), Science translational medicine, 14
Navigating Critical Challenges Associated with Immunopeptidomics-Based Detection of Proteasomal Spliced Peptide Candidates
Lichti CF. et al, (2022), Cancer Immunology Research
Investigation of chalcogen bioisosteric replacement in a series of heterocyclic inhibitors of tryptophan 2,3-dioxygenase.
Kozlova A. et al, (2021), European journal of medicinal chemistry, 227
Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J. et al, (2021), J Immunother Cancer, 9
Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-Dioxygenase.
Kozlova A. et al, (2021), Journal of medicinal chemistry, 64, 10967 - 10980
Arid5a: A Missing Link between EMT and Tumoral Immune Resistance
Van den Eynde BJ., (2021), Cancer Immunology Research
Tryptophanemia is controlled by a tryptophan-sensing mechanism ubiquitinating tryptophan 2,3-dioxygenase
Klaessens S. et al, (2021), Proceedings of the National Academy of Sciences, 118, e2022447118 - e2022447118